Abstract
All patients with medullary thyroid cancer (MTC) are routinely screened for germline mutations in the rearranged during transfection (RET) proto-oncogene. In this Practice Point commentary, we discuss a cross-sectional study by Machens and Dralle, who performed germline RET proto-oncogene mutation analysis in patients with MTC at a tertiary referral centre in Germany to reveal patterns of familial disease presentation over the generations. The study identified a typical distribution of germline RET mutations (subclassified into three accepted risk categories) in the study population, consistent with the reported literature. The investigators also attempted to obtain data on the time of appearance of RET germline mutations in previous generations of the families. The natural history of MTC and penetrance of specific RET mutations could not be clearly identified in each family because of the cross-sectional nature of the study. Nevertheless, the study re-establishes the importance of routine screening for germline RET mutations in all new cases of MTC.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wohllk N et al. (1996) Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 81: 3740–3745
Elisei R et al. (2007) RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 92: 4725–4729
Eng C et al. (1996) The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276: 1575–1579
Brandi ML et al. (2001) Guidelines for the diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86: 5658–5671
Cote GJ and Gagel RF (2003) Lessons learned from the management of a rare genetic cancer. N Engl J Med 349: 1566–1568
Machens A and Dralle H (2008) Familial prevalence and age of RET germline mutations: implications for screening. Clin Endocrinol 69: 81–87
Carlomagno F et al. (2004) Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 23: 6056–6063
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Learoyd, D., Robinson, B. Routine screening for germline RET mutations is recommended for all patients with medullary thyroid cancer. Nat Rev Endocrinol 5, 6–7 (2009). https://doi.org/10.1038/ncpendmet1020
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet1020